Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
04/2003
04/03/2003WO2003002722A3 T cell regulatory genes and methods of use thereof
04/03/2003WO2003002531A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2003002530A3 Pyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7
04/03/2003WO2002100332A3 Isoxazoline compounds having mif antagonist activity
04/03/2003WO2002099052A3 Opns as modifiers of the p53 pathway and methods of use
04/03/2003WO2002099051A3 Nits as modifiers of the p53 pathway and methods of use
04/03/2003WO2002092563A3 Protease inhibitors
04/03/2003WO2002092016A3 Therapeutic use of rank antagonists
04/03/2003WO2002088336A3 Genetically modified yt cell line and use thereof
04/03/2003WO2002086078A3 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
04/03/2003WO2002085879B1 Three-step conversion of protected taxane ester to paclitaxel
04/03/2003WO2002085296A3 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
04/03/2003WO2002085286A8 Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
04/03/2003WO2002076393A3 Antiagionecic, antitumor, chemopreventative agents
04/03/2003WO2002074738A3 Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage)
04/03/2003WO2002074230A3 A dna molecule encoding a variant paraoxonase and uses thereof
04/03/2003WO2002073213A3 Assay
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002059256A3 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
04/03/2003WO2002057413A3 Peptides for activation and inhibition of delta pkc
04/03/2003WO2002056753A3 P27 prevents cellular migration
04/03/2003WO2002044419A3 Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
04/03/2003WO2002039954A3 Novel compounds
04/03/2003WO2002036578A3 Triazine derivatives as lpaat-b inhibitors and uses thereof
04/03/2003WO2002028380A3 Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
04/03/2003WO2002024909A9 Receptor nucleic acids and polypeptides
04/03/2003WO2002022166A9 Tweak receptor agonists as anti-angiogenic agents
04/03/2003WO2002018582A9 62112, a novel human dehydrogenase and uses thereof
04/03/2003WO2002018544A9 Method and reagents for treatment of skin disorders by modulating the notch pathway
04/03/2003WO2002017852A3 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
04/03/2003WO2002014369A9 Human kininogen d5 domain polypeptides and their use
04/03/2003WO2002013808A3 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
04/03/2003WO2002012524A3 Adenovirus e1b-55k single amino acid mutants and methods of use
04/03/2003WO2002000860A3 Novel proteases
04/03/2003US20030066097 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
04/03/2003US20030065200 Taxanes having T-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
04/03/2003US20030065195 Ether compounds
04/03/2003US20030065180 Anticancer agents; kidney disease
04/03/2003US20030065174 Antiinflammatory agents; analgesics
04/03/2003US20030065035 Crystallization using mixture of solvent and water
04/03/2003US20030065029 Agent for diagnosing and treating malignant tumors
04/03/2003US20030065026 Synergistic mixture with metal compound
04/03/2003US20030065023 Anticancer agents, viricides, psychological disorders
04/03/2003US20030065018 Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
04/03/2003US20030065016 Nordihydroguaiartic derivatives for use in treatment of tumors
04/03/2003US20030065006 Viricides; anticancer agents
04/03/2003US20030065004 Androgen receptor modulators and methods for use thereof
04/03/2003US20030064999 Therapy for asthma, diarrhea
04/03/2003US20030064996 Anticarcinogenic agents, antiinflammatory agents, anticholesterol agents, antidiabetic agents
04/03/2003US20030064992 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
04/03/2003US20030064987 Immunology moderators; interleukin antagonist; anticancer agents
04/03/2003US20030064984 Anticancer agents; side effect reduction
04/03/2003US20030064983 Headaches; antiarthritic agents; respiratory system disorders; psychological disorders
04/03/2003US20030064968 Viricides, anticarcinogneic agents
04/03/2003US20030064957 Reduced toxicity; enhance efficiency; side effect reduction
04/03/2003US20030064952 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
04/03/2003US20030064944 Controlling cell differentiation, cell proliferation
04/03/2003US20030064943 High affinity TGFbeta nucleic acid ligands and inhibitors
04/03/2003US20030064942 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
04/03/2003US20030064919 Novel polypeptides and polynucleotides encoding same
04/03/2003US20030064916 Antigen peptides; medical diagnosis
04/03/2003US20030064514 Oligonucleotide for use as antiproliferative agent
04/03/2003US20030064503 Device
04/03/2003US20030064493 Methods and means for modulating PGE synthase activity
04/03/2003US20030064491 Nucleotide sequences coding enzymatic polypeptide for use in the production of anticarcinogenic and infection agents
04/03/2003US20030064475 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins and uses thereof
04/03/2003US20030064470 Ligand for use as tool in the treatment of tumors in humans
04/03/2003US20030064430 Novel steroid-activated nuclear receptors and uses therefor
04/03/2003US20030064426 Expression vector for use in the treatment of cancer and age-related defects
04/03/2003US20030064410 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids
04/03/2003US20030064385 Genes expressed in breast cancer as prognostic and therapeutic targets
04/03/2003US20030064383 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cancer
04/03/2003US20030064369 Novel proteins and nucleic acids encoding same
04/03/2003US20030064121 For use as dietary supplement, in drugs, soy protein concentrate
04/03/2003US20030064114 For vasodilatation and inhibition of transplant rejection
04/03/2003US20030064098 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
04/03/2003US20030064097 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents
04/03/2003US20030064095 Microfabricated nanopore device for sustained release of therapeutic agent
04/03/2003US20030064094 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (COPD)
04/03/2003US20030064088 Surgically implantable and sealable drug delivery device that upon contact of its contents via an interface window or port with an organ or tissue exposes a therapeutic agent to organ or tissue surface, allowing a controlled, selective diffusion
04/03/2003US20030064069 Specific binding members for TGFbeta1
04/03/2003US20030064049 Topical anti-cancer compositions and methods of use thereof
04/03/2003CA2469230A1 Antibody inhibitors of gdf-8 and uses thereof
04/03/2003CA2463039A1 1,6-naphthyridine derivatives as antidiabetics
04/03/2003CA2461898A1 Biological control of nanoparticles
04/03/2003CA2461801A1 Sphingolipids
04/03/2003CA2461663A1 Conjugated anti-psychotic drugs and uses thereof
04/03/2003CA2461631A1 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
04/03/2003CA2461532A1 Use of isogenic human cancer cells for high-throughput screening and drug discovery
04/03/2003CA2461526A1 Aptamers containing sequences of nucleic acids or nucleic acid analogues bound homologously, or in novel complexes
04/03/2003CA2461421A1 Material consisting of at least a biodegradable polymer and cyclodextrins
04/03/2003CA2461372A1 Dna sequences for human angiogenesis genes
04/03/2003CA2461363A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
04/03/2003CA2461360A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
04/03/2003CA2461219A1 Reduced toxicity cisplatin formulations and methods for using the same
04/03/2003CA2461144A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003CA2461142A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
04/03/2003CA2461132A1 1, 8-naphthyridine derivatives as antidiabetics
04/03/2003CA2461128A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders
1 ... 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 ... 2211